用于阿尔茨海默病病理学早期检测的生物标志物。
Biomarkers for early detection of Alzheimer pathology.
作者信息
Clark C M, Davatzikos C, Borthakur A, Newberg A, Leight S, Lee V M-Y, Trojanowski J Q
机构信息
Department of Neurology, University of Pennsylvania, Philadelphia, PA 19104, USA.
出版信息
Neurosignals. 2008;16(1):11-8. doi: 10.1159/000109754. Epub 2007 Dec 5.
Abstract
The increasing prevalence of Alzheimer's disease and the devastating consequences of late-life dementia motivates the drive to develop diagnostic biomarkers to reliably identify the pathology associated with this disorder. Strategies to accomplish this include the detection of altered levels of tau and amyloid in cerebrospinal fluid, the use of structural MRI to identify disease-specific patterns of regional atrophy and MRI T(1)rho to detect disease-related macromolecular protein aggregation, and the direct imaging of amyloid deposits using positron emission tomography and single photon emission computerized tomography. Success will facilitate the ability to reliably diagnose Alzheimer's disease while the symptoms of brain failure are mild and may provide objective measures of disease-modifying treatment efficacy.
摘要
阿尔茨海默病患病率的不断上升以及晚年痴呆症带来的毁灭性后果，促使人们努力开发诊断生物标志物，以可靠地识别与这种疾病相关的病理特征。实现这一目标的策略包括检测脑脊液中tau蛋白和淀粉样蛋白水平的变化，利用结构磁共振成像（MRI）识别疾病特异性的区域萎缩模式，以及利用MRI T(1)rho检测与疾病相关的大分子蛋白聚集，还包括使用正电子发射断层扫描和单光子发射计算机断层扫描对淀粉样蛋白沉积进行直接成像。取得成功将有助于在脑功能衰竭症状较轻时可靠地诊断阿尔茨海默病，并且可能为疾病修饰治疗的疗效提供客观指标。
相似文献
1
Biomarkers for early detection of Alzheimer pathology.用于阿尔茨海默病病理学早期检测的生物标志物。
Neurosignals. 2008;16(1):11-8. doi: 10.1159/000109754. Epub 2007 Dec 5.
2
2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.阿尔茨海默病神经影像学计划2014年更新：自启动以来发表论文综述
Alzheimers Dement. 2015 Jun;11(6):e1-120. doi: 10.1016/j.jalz.2014.11.001.
3
Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.阿尔茨海默病中脑脊液淀粉样蛋白-β与氟代硼吡咯（florbetapir）成像的独立信息
Brain. 2015 Mar;138(Pt 3):772-83. doi: 10.1093/brain/awu367. Epub 2014 Dec 24.
4
Critical Comparison of Different Biomarkers for Alzheimer's Disease in a Clinical Setting.临床环境中阿尔茨海默病不同生物标志物的批判性比较
J Alzheimers Dis. 2015;48(2):425-32. doi: 10.3233/JAD-150229.
5
[Biomarkers for early diagnosis of Alzheimer's disease].
Ugeskr Laeger. 2015 Jun 8;177(24).
6
Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum.阿尔茨海默病谱中血液磷酸化 tau181 的时间进程。
Brain. 2021 Feb 12;144(1):325-339. doi: 10.1093/brain/awaa399.
7
Tau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkers.tau PET 于常染色体显性阿尔茨海默病：与认知、痴呆和其他生物标志物的关系。
Brain. 2019 Apr 1;142(4):1063-1076. doi: 10.1093/brain/awz019.
8
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.阿尔茨海默病神经影像学倡议：成立以来发表论文的综述。
Alzheimers Dement. 2013 Sep;9(5):e111-94. doi: 10.1016/j.jalz.2013.05.1769. Epub 2013 Aug 7.
9
PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients.PTI-125 降低阿尔茨海默病患者的生物标志物。
J Prev Alzheimers Dis. 2020;7(4):256-264. doi: 10.14283/jpad.2020.6.
10
A comparison of the diagnostic sensitivity of MRI, CBF-SPECT, FDG-PET and cerebrospinal fluid biomarkers for detecting Alzheimer's disease in a memory clinic.在记忆门诊中比较 MRI、CBF-SPECT、FDG-PET 和脑脊液生物标志物对阿尔茨海默病的诊断灵敏度。
Dement Geriatr Cogn Disord. 2010;30(4):285-92. doi: 10.1159/000320265. Epub 2010 Sep 22.
引用本文的文献
1
Microstructural abnormalities in multiple system atrophy as revealed by conventional and rotating frame relaxation MRI parameters.常规和旋转框架弛豫MRI参数揭示的多系统萎缩中的微观结构异常。
Sci Rep. 2025 Jul 24;15(1):26954. doi: 10.1038/s41598-025-10812-6.
2
Advanced Overview of Biomarkers and Techniques for Early Diagnosis of Alzheimer's Disease.阿尔茨海默病早期诊断的生物标志物与技术高级概述
Cell Mol Neurobiol. 2023 Aug;43(6):2491-2523. doi: 10.1007/s10571-023-01330-y. Epub 2023 Feb 27.
3
Selection of single domain anti-transferrin receptor antibodies for blood-brain barrier transcytosis using a neurotensin based assay and histological assessment of target engagement in a mouse model of Alzheimer's related amyloid-beta pathology.使用神经降压素测定法筛选用于血脑屏障转胞运输的单域抗转铁蛋白受体抗体，并在阿尔茨海默病相关淀粉样β病理学的小鼠模型中进行组织学评估以确定靶标结合情况。
PLoS One. 2022 Oct 18;17(10):e0276107. doi: 10.1371/journal.pone.0276107. eCollection 2022.
4
Combined small and large magnetic nanoparticle extraction and concentration from biofluids for non-toxic detection of biomarkers.用于生物标志物无毒检测的生物流体中小尺寸和大尺寸磁性纳米颗粒的联合提取与浓缩
Sens Diagn. 2022 Jun 9;1(4):829-840. doi: 10.1039/d2sd00078d. eCollection 2022 Jul 14.
5
Potential Mechanisms Underlying Resistance to Dementia in Non-Demented Individuals with Alzheimer's Disease Neuropathology.阿尔茨海默病神经病理学但无痴呆的个体对痴呆的抵抗的潜在机制。
J Alzheimers Dis. 2022;87(1):51-81. doi: 10.3233/JAD-210607.
6
A Scoping Review of Neuromodulation Techniques in Neurodegenerative Diseases: A Useful Tool for Clinical Practice?神经调节技术在神经退行性疾病中的应用：临床实践的有用工具？——一项范围综述
Medicina (Kaunas). 2021 Feb 27;57(3):215. doi: 10.3390/medicina57030215.
7
Molecular Imaging Approaches in Dementia.分子影像学在痴呆中的应用
Radiology. 2021 Mar;298(3):517-530. doi: 10.1148/radiol.2020200028. Epub 2021 Jan 19.
8
Cerebrospinal Fluid and MRI Biomarkers in Neurodegenerative Diseases: A Retrospective Memory Clinic-Based Study.神经退行性疾病中的脑脊液和 MRI 生物标志物：一项基于回顾性记忆诊所的研究。
J Alzheimers Dis. 2020;75(3):751-765. doi: 10.3233/JAD-200175.
9
Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions.阿尔茨海默病及其他疾病中 tau 和淀粉样蛋白-β 蛋白病变的影像学研究。
Nat Rev Neurol. 2018 Apr;14(4):225-236. doi: 10.1038/nrneurol.2018.9. Epub 2018 Feb 16.
10
Beta-Band Functional Connectivity is Reorganized in Mild Cognitive Impairment after Combined Computerized Physical and Cognitive Training.在联合计算机化身体和认知训练后，轻度认知障碍患者的β波段功能连接发生重组。
Front Neurosci. 2016 Feb 29;10:55. doi: 10.3389/fnins.2016.00055. eCollection 2016.
本文引用的文献
1
Commentary on "Optimal design of clinical trials for drugs designed to slow the course of Alzheimer's disease." Biochemical biomarkers of late-life dementia.对“旨在延缓阿尔茨海默病病程的药物临床试验的优化设计”的评论。晚年痴呆的生化生物标志物。
Alzheimers Dement. 2006 Oct;2(4):287-93. doi: 10.1016/j.jalz.2006.05.2347.
2
Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics.用于诊断和监测治疗的神经退行性变生物标志物。
Nat Rev Drug Discov. 2007 Apr;6(4):295-303. doi: 10.1038/nrd2176. Epub 2007 Mar 9.
3
Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study.阿尔茨海默病中的淀粉样蛋白、代谢减退与认知：一项[11C]PIB和[18F]FDG正电子发射断层显像研究
Neurology. 2007 Feb 13;68(7):501-8. doi: 10.1212/01.wnl.0000244749.20056.d4. Epub 2006 Oct 25.
4
In vivo measurement of plaque burden in a mouse model of Alzheimer's disease.在阿尔茨海默病小鼠模型中对斑块负荷进行体内测量。
J Magn Reson Imaging. 2006 Nov;24(5):1011-7. doi: 10.1002/jmri.20751.
5
Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease.基于体素的正电子发射断层显像淀粉样蛋白配体[11C]PIB摄取在阿尔茨海默病中的分析。
Neurology. 2006 Nov 14;67(9):1575-80. doi: 10.1212/01.wnl.0000240117.55680.0a. Epub 2006 Sep 13.
6
[11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease.非痴呆人群中的[11C]匹兹堡化合物B：阿尔茨海默病的潜在前驱标志物。
Neurology. 2006 Aug 8;67(3):446-52. doi: 10.1212/01.wnl.0000228230.26044.a4.
7
Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.阿尔茨海默病患者淀粉样蛋白沉积的两年随访
Brain. 2006 Nov;129(Pt 11):2856-66. doi: 10.1093/brain/awl178. Epub 2006 Jul 19.
8
Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study.阿尔茨海默病中的淀粉样蛋白负荷与脑萎缩：一项¹¹C-PIB正电子发射断层扫描研究
Ann Neurol. 2006 Jul;60(1):145-7. doi: 10.1002/ana.20889.
9
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.轻度认知障碍患者脑脊液生物标志物与早期阿尔茨海默病的关联：一项随访研究。
Lancet Neurol. 2006 Mar;5(3):228-34. doi: 10.1016/S1474-4422(06)70355-6.
10
Global prevalence of dementia: a Delphi consensus study.痴呆症的全球患病率：一项德尔菲共识研究。
Lancet. 2005 Dec 17;366(9503):2112-7. doi: 10.1016/S0140-6736(05)67889-0.
Zotero 插件